| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Arena Pharmaceuticals, Inc. |
| 6166 Nancy Ridge Drive, San Diego, CA 92121 * (858) 453-7200 |
| Business Description | The company is a biotechnology company that has developed a broadly applicable platform technology that identifies drug candidates more efficiently then traditional drug discovery techniques. |
| Offering Information Company has | |||
| Trading As | ARNA (NASNTL) | Industry | Service (SIC 8734) |
| Type of Stock Offered | Common Shares | Filing Date | 4/28/00 |
| Domestic Shares Offered | 6,000,000 | Offer Date | 7/27/00 |
| Foreign Shares Offered | 0 | Filing Range | $15.00 - $17.00 |
| Company Shares | 6,000,000 | Offer Price | $18.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.750 |
| Gross Proceeds | $108,000,000 | Selling | $0.100 |
| Expenses | - - | Reallowance | - - |
| Post-IPO Shares | 19,690,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| ING Baring Furman Selz | Lead Manager | (212) 309-8200 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | ||
| Revenues | - | - | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | -0.695 | -3.396 | -10.238 | -1.998 | -2.894 |
| E.P.S | - | - | - | - | -1.290 | - | -0.430 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.67 | -1.09 | -2.92 | ||||
| Cash Flow - Inv. | -2.11 | -0.25 | -0.15 | ||||
| Cash Flow - Fin. | 15.98 | 14.51 | 25.21 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 30.70 | Current Assets | 27.71 | Current Ratio | 30.80 |
| Total Liab. | 47.10 | Current Liab. | 0.90 | Debt Ratio | 153.40% |
| Total Equity | -16.39 | Working Cap. | 26.81 | Debt to Equity Ratio | - |
| Cash | 27.55 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes, including working capital, research and development and clinical testing, and potentially for acquisitions of complementary businesses or technologies. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Morgan, Lewis & Bockius |
| Bank's Law Firm | Winthrop, Stimson, Putnam & Roberts |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| MPM Asset Management | 28.10 | |
| International BM Biomedicine Holdings, Inc. | 13.50 | |
| Eaton Vance Worldwide Health Sciences Fund | 5.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||